We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Amivantamab Plus Lazertinib Shows Promising Activity in Atypical EGFR-Mutant Advanced NSCLC: CHRYSALIS‑2 Cohort C Results

MedXY Editorial Team•Dec 8, 2025•news
amivantamablazertinibNon-Small Cell Lung Cancer

Highlights

– Amivantamab plus lazertinib produced an investigator-assessed objective response rate (ORR) of 52% in 105 patients with atypical EGFR‑mutant advanced NSCLC (median follow‑up 16.1 months).

– Responses were durable (median duration of response 14.1 months) and deeper and longer in treatment‑naïve patients (ORR 57%; mPFS 19.5 months; mDoR 20.7 months).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Resection Extent in Non-Small Cell Lung Cancer: Margin Positivity is Unrelated to Surgical ScopeA recent study demonstrates that positive surgical margins in non-small cell lung cancer (NSCLC) do not vary significantly with resection type, supporting selective use of wedge resection without compromising oncologic outcomes.Aug 14, 2026Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch TrialThis post hoc analysis of the Neotorch phase 3 trial demonstrates that adding toripalimab to chemotherapy perioperatively in stage III resectable NSCLC improves tumor and nodal downstaging, reduces surgery cancellation, and significantly enJul 20, 2026Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in JapanA nationwide Japanese cohort study found that patients with schizophrenia spectrum disorder and NSCLC presented with more advanced disease and were less likely to receive surgery, adjuvant chemotherapy, or systemic therapy.May 29, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Amivantamab Falls Short of Tumor Shrinkage in Recurrent or Metastatic Adenoid Cystic Carcinoma, but Disease Stabilization Was Common
In a phase 2 trial, amivantamab did not meet its primary response endpoint in recurrent/metastatic adenoid cystic carcinoma, but most patients achieved stable disease and toxicity was generally manageable.
Apr 20, 2026
Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy RechallengeA nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.Apr 14, 2026
Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic CarcinomaA Phase 2 clinical trial of amivantamab, an EGFR-MET bispecific antibody, in recurrent or metastatic adenoid cystic carcinoma (ACC) showed a 72.2% clinical benefit rate. While the primary objective response rate was low, the high rate of diMar 2, 2026